

Freedom of Information Request: 0338 2019/20

University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.

Queen Elizabeth Hospital Birmingham:

This is a freedom of information request relating to patients being treated for multiple myeloma or chronic lymphocytic leukaemia.

1. **Does your trust treat adult multiple myeloma [MM] ? Yes**
 - a. **if you refer your multiple myeloma patients to another centre, please state which.** Not Applicable

2. **If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;**
 - Bortezomib [Velcade] - 8**
 - Carfilzomib [Kyprolis] - 0**
 - Ixazomib [Ninlaro] - 3**
 - Lenalidomide [Revlimid]- 10**
 - Daratumumab [Darzalex] - 3**
 - Melphalan, prednisolone and thalidomide (known as MPT) - 0**
 - Cyclophosphamide, thalidomide and dexamethasone (known as CTD) - 2**
 - Pomalidomide [Imnovid] - 3**

3. **Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?**
 - a. **If possible, how many CLL patients treated were new to therapy in the past 3 months?**

We do not hold this information

4. **How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;**
 - **Fludarabine (Fludara), cyclophosphamide (Cytosan), and rituximab (known as FCR) - 1**
 - **Bendamustine and rituximab (known as BR) - 0**
 - **Ibrutinib [Imbruvica] - 4**
 - **Chlorambucil - 0**
 - **Venetoclax - 2**
 - **Obinutuzumab - 0**
 - **Idelalisib - 0**
 - **Fludarabine and rituximab (known as FR) - 1**
 - **High-dose prednisone and rituximab - 0**
 - **Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR) - 0**
 - **Alemtuzumab (Campath) with rituximab - 0**

Heartlands, Good Hope and Solihull Hospitals:

This is a freedom of information request relating to patients being treated for multiple myeloma or chronic lymphocytic leukaemia.

1. **Does your trust treat adult multiple myeloma [MM] ? Yes**
 - b. **if you refer your multiple myeloma patients to another centre, please state which. Not Applicable**

2. **If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;**
 - Bortezomib [Velcade] - 2 (with Daratumumab – 7)**
 - Carfilzomib [Kyprolis] - 1**
 - Ixazomib [Ninlaro] - 1 (with Lenalidomide – 18)**
 - Lenalidomide [Revlimid]- 19 (with Ixazomib – 18)**
 - Daratumumab [Darzalex] - 10 (with Bortezomib – 7, Pomalidomide – 1)**
 - Melphalan, prednisolone and thalidomide (known as MPT) - 0**
 - Cyclophosphamide, thalidomide and dexamethasone (known as CTD) - 1**
 - Pomalidomide [Imnovid] - 4**

3. **Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?**
 - a. **If possible, how many CLL patients treated were new to therapy in the past 3 months?**

We do not hold this information

4. **How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;**
 - **Fludarabine (Fludara), cyclophosphamide (Cytosan), and rituximab (known as FCR) - 0**
 - **Bendamustine and rituximab (known as BR) - 0**
 - **Ibrutinib [Imbruvica] - 6**
 - **Chlorambucil - 1 (with Obinutuzumab – 1)**
 - **Venetoclax - 2**
 - **Obinutuzumab - (with Chlorambucil – 1)**
 - **Idelalisib - 0**
 - **Fludarabine and rituximab (known as FR) – 0**
 - **High-dose prednisone and rituximab – 0**
 - **Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR) – 0**
 - **Alemtuzumab (Campath) with rituximab – 0**